Home / Market News / $REGN
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Leerink Partners Adjusts Price Target on Regeneron Pharmaceuticals to $997 From $835

Nov 2, 2026, 11:33 AM UTC · Primary ticker $REGN

Leerink Partners has increased its price target for Regeneron Pharmaceuticals (REGN) to $997 from $835, indicating a more optimistic outlook on the company's valuation. This revision aligns with the broader analyst consensus, which maintains an 'Overweight' rating and an average price target of $973.04 for REGN.

Leerink Partners has raised its price target for Regeneron Pharmaceuticals (REGN) by a significant margin, from $835 to $997. This upward revision suggests that Leerink sees greater upside potential in REGN's stock, likely due to updated financial models or positive developments within the company's pipeline or market position. This news is generally positive for REGN as it reinforces investor confidence and could attract new buyers, potentially leading to short-term price appreciation. For traders, this indicates a bullish sentiment from a notable investment bank, aligning with the overall 'Overweight' consensus from other analysts. The key opportunity lies in potential upward momentum if the market reacts favorably to this revised valuation, though the impact might be moderate given it's an analyst revision rather than a fundamental company announcement.

$REGN positive Increased price target from Leerink Partners
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.